A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help with weight.

Who can join

Children and teens 12 to 17, have obesity.

What you take

orforglipron, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.

How long it lasts

The full study runs about 6.2 years; your own time in it is usually shorter.

What you get

The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.

What this study is for

Full study title: A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities.

Primary condition: Obesity. Also studied in: Overweight.

Who can join, in detail

Key inclusion criteria

• Have a history of at least 1 unsuccessful effort to lose sufficient body weight after participation in a structured lifestyle modification program (diet and exercise counseling for at least 3 months) prior to screening.
• Obesity as defined by BMI equal to or above the 95th percentile for age and sex (on age- and gender-specific growth chart [CDC-NCHS, 2022]); OR
• Overweight as defined by BMI equal to or above the 85th percentile but less than the 95th percentile for age and sex, on age- and sex-specific growth chart (CDC-NCHS, 2022), and at least 1 weight-related comorbidity,
• hypertension
• type 2 diabetes (T2D)

Key exclusion criteria

• Prepubertal (Tanner stage 1)
• Have a self-reported, or by parent or legal guardian where applicable, decrease in body weight greater than 5 kilograms (kg) (11 pounds) within 90 days before screening
• Have undergone or plan to undergo weight reduction procedure during the study, such as, but not limited to:
• gastric bypass
• sleeve gastrectomy

Where this study is enrolling

This trial has 14 US sites across 12 states. Contact the site coordinator directly to start the screening process.

Timeline

Started enrolling: 2024-11-18. Expected completion: 2031-01. Last updated on ClinicalTrials.gov: 2026-05-27.

Official source

We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:

View on ClinicalTrials.gov →

Other GLP-1 clinical trials

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and editorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas. About this site · LinkedIn · Contact